Mirae Asset Capital Life Science

Mirae Asset Capital Life Science was formed in 2023 as a joint venture between Mirae Asset Capital and Mirae Asset Global Investments.

It is the first and only U.S. affiliate for Mirae Asset dedicated to investment in Life Science.

Near-Term Value

• The majority of our investments will be Series A/B and entering the clinic within a few years to generate real value with clinical proof of concept
• We believe companies at this stage maximize returns given the risk; we remain open to seed opportunities where there is a clear path to value and Series C opportunities if the valuation and resulting equity ownership support meaningful returns to our investors
• We aim to find the right mix between first-in-class and best-in-class assets with meaningful market share and evaluate both platform and single asset approaches

Calculated Risk

• We are modality agnostic when it comes to therapeutics and incredibly opportunistic with diagnostics
• Our interest in digital health involves using AI/ML tools (e.g. quantum computing, generative biology/chemistry) for drug discovery or protein engineering
• We co-invest with top-tier life science investors who we know and have worked with before and leverage our operational experience to find strong management teams with excellent track records relevant to the company they are building
• We aim to be active investors by securing board roles whenever possible; this is a role that is familiar to us and helps mitigate risk to our investors by helping to shape the course of our investments

Innovative yet Validated Modalities

• We have selected five core therapeutic sectors to focus our investments: Oncology, Immunology, CV/Metabolic, CNS/Ophthalmology, and Rare/Genetic Disease
• For each of the above sectors we have defined various focus areas defined by a unique combination of validation, unmet need, market potential, and acquisition/public market interest
• We seek to limit biological and technical risk and prioritize small molecule, antibody approaches (includes mAbs, bsAbs/TCEs, ADCs, radiotherapeutics), and nucleic acid therapeutics (siRNA, ASOs) across these sectors

Rigorous Evaluation

• We leverage the combined scientific background of our team and our affiliates in Asia (medicinal chemistry, pharmacology, structural biology) to perform rigorous evaluation of each investment
• We prepare a comprehensive diligence memo for each investment that includes a thorough evaluation of the science, pipeline, finance, management, board, investors, operations, regulatory, IP, clinical development, and potential return to our investors
• We conduct calls with relevant Key Opinion Leaders for every opportunity to ensure we have the most informed and updated views from the leading voices in the field